Literature DB >> 18981306

A randomized trial of on-pump beating heart and conventional cardioplegic arrest in coronary artery bypass surgery patients with impaired left ventricular function using cardiac magnetic resonance imaging and biochemical markers.

Tammy J Pegg1, Joseph B Selvanayagam, Jane M Francis, Theodoros D Karamitsos, Zoe Maunsell, Ly-Mee Yu, Stefan Neubauer, David P Taggart.   

Abstract

BACKGROUND: Beating heart coronary artery bypass grafting (CABG) improves early postoperative cardiac function in patients with normal ventricular function, but its effect in patients with impaired function is uncertain. We compared a novel hybrid technique of on-pump beating heart CABG (ONBEAT) with conventional on-pump CABG (ONSTOP) in patients with impaired ventricular function. METHODS AND
RESULTS: In a single-center randomized trial, 50 patients with impaired ventricular function were randomly assigned to ONBEAT or ONSTOP. Patients underwent cardiac magnetic resonance imaging for function and delayed hyperenhancement early and later after surgery. Serial assessment of biochemical markers was also undertaken. Preoperative characteristics were well matched; cardiac index was 2.85+/-0.53 (ONBEAT) and 2.62+/-0.59 L x min(-1) x m(-2) (ONSTOP). Early after surgery, there was a trend toward a greater reduction in end-systolic volume index in ONSTOP patients versus ONBEAT (-9+/-8 versus -4+/-11 mL x m(-2); P=0.06). The changes were sustained and significant at 6 months (-14+/-18 versus -2+/-19 mL x m(-2); P=0.04). Furthermore, the incidence of new hyperenhancement at 6 days was higher in ONBEAT patients (P=0.05), with 6 of 17 (35%) sustaining 8.2+/-5.2 g of new hyperenhancement each versus 2 of 23 (9%) in the ONSTOP group, each with 9.8+/-9.0 g (P=0.86). Finally, median area under the curve for troponin was higher in ONBEAT at 461 (interquartile range, 226 to 1141) microg/L versus 160 (interquartile range, 98 to 357) microg/L for ONSTOP (P=0.002).
CONCLUSIONS: The incidence of new irreversible myocardial injury was significantly higher in ONBEAT than in ONSTOP patients. Furthermore, at 6 months, only ONSTOP patients demonstrated an improvement in ventricular geometry. The most likely mechanism is inadequate coronary perfusion to distal myocardial territories in patients with severe proximal coronary disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18981306     DOI: 10.1161/CIRCULATIONAHA.108.785105

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  15 in total

Review 1.  Cardioprotection during cardiac surgery.

Authors:  Derek J Hausenloy; Edney Boston-Griffiths; Derek M Yellon
Journal:  Cardiovasc Res       Date:  2012-03-22       Impact factor: 10.787

Review 2.  Diagnostic dilemma of perioperative myocardial infarction after coronary artery bypass grafting: A review.

Authors:  Viola Weidenmann; N Bryce Robinson; Lisa Q Rong; Irbaz Hameed; Ajita Naik; Mahmoud Morsi; Philippe Grieshaber; Andreas Böning; Leonard N Girardi; Mario Gaudino
Journal:  Int J Surg       Date:  2020-05-19       Impact factor: 6.071

Review 3.  Revascularization options in patients with chronic kidney disease.

Authors:  Guha Ashrith; MacArthur A Elayda; James M Wilson
Journal:  Tex Heart Inst J       Date:  2010

4.  Myocardial revascularization using on-pump beating heart among patients with left ventricular dysfunction.

Authors:  Ahmad K Darwazah; Vivian Bader; Ismail Isleem; Khalil Helwa
Journal:  J Cardiothorac Surg       Date:  2010-11-10       Impact factor: 1.637

5.  On-pump beating heart versus off-pump myocardial revascularization-a propensity-matched comparison.

Authors:  Yashaskar Manjunatha Rao; Shreyas Potdar; Debasis Das; Atanu Saha; Lalit Kapoor; Mrinalendu Das; Pradeep Narayan
Journal:  Indian J Thorac Cardiovasc Surg       Date:  2021-10-06

Review 6.  Inhaled nitric oxide: role in the pathophysiology of cardio-cerebrovascular and respiratory diseases.

Authors:  Lorenzo Berra; Emanuele Rezoagli; Davide Signori; Aurora Magliocca; Kei Hayashida; Jan A Graw; Rajeev Malhotra; Giacomo Bellani
Journal:  Intensive Care Med Exp       Date:  2022-06-27

7.  Prediction of global left ventricular functional recovery in patients with heart failure undergoing surgical revascularisation, based on late gadolinium enhancement cardiovascular magnetic resonance.

Authors:  Tammy J Pegg; Joseph B Selvanayagam; Joslin Jennifer; Jane M Francis; Theodoros D Karamitsos; Erica Dall'Armellina; Karen L Smith; David P Taggart; Stefan Neubauer
Journal:  J Cardiovasc Magn Reson       Date:  2010-10-07       Impact factor: 5.364

8.  On-Pump Beating/Non-Beating CABG in Stable Angina Have Similar Outcomes.

Authors:  Victor Dayan; Juan Jose Paganini; Alvaro Marichal; Daniel Brusich
Journal:  Braz J Cardiovasc Surg       Date:  2018 Mar-Apr

9.  Hypotheses, rationale, design, and methods for prognostic evaluation of cardiac biomarker elevation after percutaneous and surgical revascularization in the absence of manifest myocardial infarction. A comparative analysis of biomarkers and cardiac magnetic resonance. The MASS-V Trial.

Authors:  Whady Hueb; Bernard J Gersh; Paulo Cury Rezende; Cibele Larrosa Garzillo; Eduardo Gomes Lima; Ricardo D'Oliveira Vieira; Rosa Maria Rahmi Garcia; Desiderio Favarato; Carlos Alexandre W Segre; Alexandre Costa Pereira; Paulo Rogério Soares; Expedito Ribeiro; Pedro Lemos; Marco A Perin; Célia Cassaro Strunz; Luis A O Dallan; Fabio B Jatene; Noedir A G Stolf; Alexandre Ciappina Hueb; Ricardo Dias; Fabio A Gaiotto; Leandro Menezes Alves da Costa; Fernando Teiichi Costa Oikawa; Rodrigo Morel Vieira de Melo; Carlos Vicente Serrano; Luiz Francisco Rodrigues de Ávila; Alexandre Volney Villa; José Rodrigues Parga Filho; César Nomura; José A F Ramires; Roberto Kalil Filho
Journal:  BMC Cardiovasc Disord       Date:  2012-08-16       Impact factor: 2.298

Review 10.  Cardiovascular MRI in clinical trials: expanded applications through novel surrogate endpoints.

Authors:  Alex Pitcher; Deborah Ashby; Paul Elliott; Steffen E Petersen
Journal:  Heart       Date:  2011-06-29       Impact factor: 5.994

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.